Tesamorelin
$147.00 – $1,190.00
Tesamorelin, is a growth-hormone-releasing hormone (GHRH) analogue used clinically for the treatment of HIV-associated lipodystrophy. It is also being researched for its ability to improve peripheral nerve health, slow the progression of mild cognitive impairment, and the reduction fat mass..
Description
Tesamorelin Structure
Name: Tesamorelin; Egrifta
CAS No.: 901758-09-6
Peptide Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Molecular Formula: C221H366N72O67S•C2H4O2
Molecular Weight: 5195.9
Appearance: White Lyophilized powder
Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada.
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group
Tesamorelin is used for Reducing excess stomach fat in certain HIV-infected patients.
Tesamorelin is a human growth hormone-releasing factor (GRF) analog. It works by stimulating the pituitary gland to release growth hormone (GH). This causes the breakdown of excess stomach fat.
Product use: This product is only for research chemicals.
Additional information
| Size |
|---|
Reviews
There are no reviews yet.